Early lymph node check is saving lives in melanoma patients
19 October 2017
Research presented this week at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides.
This biopsy, which looks for cancer cells in the lymph nodes, can identify patients whose melanoma has spread beyond the site on the skin (Stage III melanoma) and who may be suitable to receive the new generation of anti-melanoma drugs.
The recently published Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma recommends that “sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.8 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive”.
“We know patients who have melanoma cells present in their draining lymph nodes (Stage III) are up to three times more likely to die from their melanoma than patients where the lymph nodes are clear,” says David Gyorki, a consultant surgeon and melanoma specialist at the Peter MacCallum Cancer Centre.
“For some time, we’ve known that sentinel lymph node biopsy is an excellent way to identify those patients who have a higher risk of having their disease progress, and with the new drugs we have gained the tools to respond and to reduce this risk.
“On the horizon, we will have access to effective, well tolerated drug therapies that can reduce the risk of relapse and, using sentinel lymph node biopsy to identify appropriate patients, the data indicate that this strategy is saving lives.”
For most patients diagnosed with melanoma, their disease is localised and effectively treated with surgery; however, some patients’ disease will progress. Of the 14,000 Australians diagnosed with melanoma each year, almost 15% will die from their disease.
Findings from recent clinical trials have demonstrated a major improvement in survival for patients with Stage III melanoma using drug therapy after surgery with the aim to prevent the melanoma from appearing in distant organs (Stage IV disease).
In one such clinical trial, known as COMBI-AD, patients who received a combination of targeted therapies (dabrafenib and trametinib) decreased the chance of their melanoma progressing by 53% compared to the current standard therapy of ‘watch and wait’.
“We encourage clinicians to inform their patients about sentinel lymph node biopsy so that patients can properly understand their risk of recurrence and death from melanoma, and therefore discuss the option of further drug therapy” says Professor Georgina Long, Medical Oncologist and Co-Medical Director of Melanoma Institute Australia.
The 9th World Congress of Melanoma is underway in Brisbane, October 18 – 21.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.